无法切除的肝癌患者在接受阿特珠单抗加贝伐单抗治疗后接受来伐替尼治疗的安全性评估：来伐替尼作为一线或二线治疗的比较

{"title":"无法切除的肝癌患者在接受阿特珠单抗加贝伐单抗治疗后接受来伐替尼治疗的安全性评估：来伐替尼作为一线或二线治疗的比较","authors":"M. Kimura, Shiori Yamada, M. Go, S. Yasuda, H. Toyoda, E. Usami","doi":"10.3892/ol.2024.14464","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":508560,"journal":{"name":"Oncology Letters","volume":"43 13","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety evaluation of lenvatinib treatment after atezolizumab plus bevacizumab therapy for patients with unresectable liver cancer: A comparison of lenvatinib as 1st‑ or 2nd‑line treatment\",\"authors\":\"M. Kimura, Shiori Yamada, M. Go, S. Yasuda, H. Toyoda, E. Usami\",\"doi\":\"10.3892/ol.2024.14464\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":508560,\"journal\":{\"name\":\"Oncology Letters\",\"volume\":\"43 13\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology Letters\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3892/ol.2024.14464\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Letters","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3892/ol.2024.14464","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}